Current Scheduling Status
None
Year(s) and type of review / ECDD meetings
Drug Class
Recommendation (from TRS)
Substance identification
(+)-N-Hydroxytenamfetamine (CAS 74698-47-8), chemically N-[alpha-methyl-3,4-(methylenedioxy)phenethyl]hydroxylamine, is also known as N-hydroxyMDA, 3,4-methylenedioxy-N-hydroxyamphetamine, N-hydroxy-3,4-methylenedioxyamphetamine, N-OH-MDA, N-hydroxy-3,4-methylenedioxyphenylisopropylamine and 1-(3,4-methylenedioxyphenyl)-2 hydroxyaminopropane. There is one chiral carbon atom in the molecule so that two stereoisomers and one racemate are possible.
Similarity to known substances and effects on the CNS
In rodent studies, (+)-N-hydroxytenamfetamine was shown to be a psychomotor stimulant. In drug discrimination studies in rats, the substance did not generalize to either d-amfetamine or (+)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). In humans, it was reported to have psychotomimetic activity at relatively high doses.
Dependence potential
In self-administration studies in the baboon, (+)-N-hydroxytenamfetamine was reinforcing. The substance produced an amfetamine-like pattern of intake. The laboratory that carried out these studies previously reported that (+)-N-methyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine (MDMA) was self-administered by baboons in a similar experiment.
Actual abuse and or/evidence of likelihood of abuse
No data are available on actual abuse, but (+)-Nhydroxytenamfetamine has been identifieidn illicit traffic.in both the USA and Europe. Clandestine production has been reported.
Therapeutic usefulness
There is no known therapeutic use for (+)-N-hydroxytenamfetamine.
Recommendation
On the basis of the data concerning its pharmacological profile, dependence potential and actual abuse, the Committee rated the likelihood of abuse of (+)-N-hydroxytenamfetamine as moderate. The public health and social problems associated with the substance are not serious at the present time; it has no known therapeutic use. The Committee found that there was sufficient evidence that (+)-N-hydroxytenamfetamine is being, or is likely to be, abused so as to constitute a public health and social problem warranting the placing of the substance under international control. In the light of this-assessment, the Committee recommended that (+)-N-hydroxytenamfetamine be controlled under Schedule I of the Convention on Psychotropic Substances, 1971.
(+)-N-Hydroxytenamfetamine (CAS 74698-47-8), chemically N-[alpha-methyl-3,4-(methylenedioxy)phenethyl]hydroxylamine, is also known as N-hydroxyMDA, 3,4-methylenedioxy-N-hydroxyamphetamine, N-hydroxy-3,4-methylenedioxyamphetamine, N-OH-MDA, N-hydroxy-3,4-methylenedioxyphenylisopropylamine and 1-(3,4-methylenedioxyphenyl)-2 hydroxyaminopropane. There is one chiral carbon atom in the molecule so that two stereoisomers and one racemate are possible.
Similarity to known substances and effects on the CNS
In rodent studies, (+)-N-hydroxytenamfetamine was shown to be a psychomotor stimulant. In drug discrimination studies in rats, the substance did not generalize to either d-amfetamine or (+)-1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). In humans, it was reported to have psychotomimetic activity at relatively high doses.
Dependence potential
In self-administration studies in the baboon, (+)-N-hydroxytenamfetamine was reinforcing. The substance produced an amfetamine-like pattern of intake. The laboratory that carried out these studies previously reported that (+)-N-methyl-alpha-methyl-3,4-(methylenedioxy)phenethylamine (MDMA) was self-administered by baboons in a similar experiment.
Actual abuse and or/evidence of likelihood of abuse
No data are available on actual abuse, but (+)-Nhydroxytenamfetamine has been identifieidn illicit traffic.in both the USA and Europe. Clandestine production has been reported.
Therapeutic usefulness
There is no known therapeutic use for (+)-N-hydroxytenamfetamine.
Recommendation
On the basis of the data concerning its pharmacological profile, dependence potential and actual abuse, the Committee rated the likelihood of abuse of (+)-N-hydroxytenamfetamine as moderate. The public health and social problems associated with the substance are not serious at the present time; it has no known therapeutic use. The Committee found that there was sufficient evidence that (+)-N-hydroxytenamfetamine is being, or is likely to be, abused so as to constitute a public health and social problem warranting the placing of the substance under international control. In the light of this-assessment, the Committee recommended that (+)-N-hydroxytenamfetamine be controlled under Schedule I of the Convention on Psychotropic Substances, 1971.
ECDD Recommendation
Inclusion in Schedule I of the 1971 Convention on Psychotropic Substances
Link to full TRS
who_trs_787.pdf1.19 MB